Search research articles
Contact Us
Filters
Showing results (21-30 of 27) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 27 results.
The Lancet. Psychiatry
|
April 10, 2025
Efficacy and safety of brexpiprazole in adolescents with schizophrenia: a multicountry, randomised, double-blind, placebo-controlled, phase 3 trial with an active reference
Caroline Ward, Milica Pejović Milovančević, Eva Kohegyi, et al.
Journal of Alzheimer'S Disease : JAD
|
November 13, 2024
Brexpiprazole for the treatment of agitation associated with dementia due to Alzheimer's disease: A 12-week, active-treatment, extension trial
Saloni Behl, Mary Slomkowski, Dalei Chen, et al.
JAMA Neurology
|
November 6, 2023
Brexpiprazole for the Treatment of Agitation in Alzheimer Dementia: A Randomized Clinical Trial
Daniel Lee, Mary Slomkowski, Nanco Hefting, et al.
Journal of Affective Disorders
|
October 21, 2023
Consistency checks to improve measurement with the Young Mania Rating Scale (YMRS)
Jonathan Rabinowitz, Robert C Young, Christian Yavorsky, et al.
Journal of Affective Disorders
|
February 1, 2022
Consistency checks to improve measurement with the Hamilton Rating Scale for Depression (HAM-D)
Jonathan Rabinowitz, Janet B W Williams, Ariana Anderson, et al.
Journal of Affective Disorders
|
January 13, 2023
Consistency checks to improve measurement with the Hamilton Rating Scale for Anxiety (HAM-A)
Jonathan Rabinowitz, Janet B W Williams, Nanco Hefting, et al.
CNS Drugs
|
July 18, 2025
Safety and Tolerability of Brexpiprazole in Participants with Agitation Associated with Dementia due to Alzheimer's Disease: Pooled Analysis of Three Randomized Trials and an Extension Trial
Alpesh Shah, Alvin Estilo, Pamela L Sheridan, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 27) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 27 results.
The Lancet. Psychiatry
|
April 10, 2025
Efficacy and safety of brexpiprazole in adolescents with schizophrenia: a multicountry, randomised, double-blind, placebo-controlled, phase 3 trial with an active reference
Caroline Ward, Milica Pejović Milovančević, Eva Kohegyi, et al.
Journal of Alzheimer'S Disease : JAD
|
November 13, 2024
Brexpiprazole for the treatment of agitation associated with dementia due to Alzheimer's disease: A 12-week, active-treatment, extension trial
Saloni Behl, Mary Slomkowski, Dalei Chen, et al.
JAMA Neurology
|
November 6, 2023
Brexpiprazole for the Treatment of Agitation in Alzheimer Dementia: A Randomized Clinical Trial
Daniel Lee, Mary Slomkowski, Nanco Hefting, et al.
Journal of Affective Disorders
|
October 21, 2023
Consistency checks to improve measurement with the Young Mania Rating Scale (YMRS)
Jonathan Rabinowitz, Robert C Young, Christian Yavorsky, et al.
Journal of Affective Disorders
|
February 1, 2022
Consistency checks to improve measurement with the Hamilton Rating Scale for Depression (HAM-D)
Jonathan Rabinowitz, Janet B W Williams, Ariana Anderson, et al.
Journal of Affective Disorders
|
January 13, 2023
Consistency checks to improve measurement with the Hamilton Rating Scale for Anxiety (HAM-A)
Jonathan Rabinowitz, Janet B W Williams, Nanco Hefting, et al.
CNS Drugs
|
July 18, 2025
Safety and Tolerability of Brexpiprazole in Participants with Agitation Associated with Dementia due to Alzheimer's Disease: Pooled Analysis of Three Randomized Trials and an Extension Trial
Alpesh Shah, Alvin Estilo, Pamela L Sheridan, et al.
Page
of 3